SCHEMBL21652025

SCHEMBL21652025

CCN1CCC(NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.68
SLC6A12 P48065 1/20 0.68
TMEM97 Q5BJF2 1/20 0.68
SIGMAR1 Q99720 1/20 0.68
RECQL P46063 1/20 0.67
CCR3 P51677 3/20 0.62
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 2/20 0.60
SLC6A5 Q9Y345 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.58
DRD2 P14416 1/20 0.58
DRD4 P21917 1/20 0.58
HTR1A P08908 1/20 0.57
HTR7 P34969 1/20 0.57
CTSB P07858 1/20 0.56
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
CTSC P53634 1/20 0.56
USP2 O75604 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560294 0.87 SLC6A5 (0.58) MCHR1SLC6A12TMEM97SIGMAR1RECQL
SCHEMBL18286474 0.85 CARM1 (0.72) MCHR1SLC6A12TMEM97SIGMAR1KMT2A
SCHEMBL21651961 0.84 CCR3 (0.67) MCHR1CCR3KMT2AL3MBTL1HTR7
SCHEMBL4749226 0.84 NPC1 (0.67) MCHR1SLC6A12TMEM97SIGMAR1CCR3
SCHEMBL11223577 0.83 MCHR1 (0.65) MCHR1SLC6A12TMEM97SIGMAR1CCR3
SCHEMBL6379927 0.83 MCHR1 (0.69) MCHR1SLC6A12TMEM97SIGMAR1CCR3
SCHEMBL3537578 0.82 L3MBTL1 (0.52) MCHR1SLC6A12TMEM97SIGMAR1RECQL
SCHEMBL6378472 0.81 MCHR1 (0.66) MCHR1SLC6A12TMEM97SIGMAR1CCR3
SCHEMBL7377018 0.81 MCHR1 (0.59) MCHR1SLC6A12TMEM97SIGMAR1CCR3
SCHEMBL1425074 0.81 SIGMAR1 (1.00) MCHR1SLC6A12TMEM97SIGMAR1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MCHR1 1063/4885SLC6A12 4430/4885TMEM97 4256/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MCHR1 1063/4885SLC6A12 4430/4885TMEM97 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.